
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
Prenetics Holding Company Limited (PRENW)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: PRENW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $0
1 Year Target Price $0
0 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 1 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.17 | 52 Weeks Range 0.01 - 0.05 | Updated Date 06/21/2025 |
52 Weeks Range 0.01 - 0.05 | Updated Date 06/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.04 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -115.91% | Operating Margin (TTM) -61.41% |
Management Effectiveness
Return on Assets (TTM) -14.52% | Return on Equity (TTM) -28.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 9154745 |
Shares Outstanding - | Shares Floating 9154745 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Prenetics Holding Company Limited
Company Overview
History and Background
Prenetics Holding Company Limited was founded in 2013. It has evolved from a DNA testing company to a global leader in genomic and diagnostic testing, focusing on early disease detection and personalized healthcare.
Core Business Areas
- Genomic and Diagnostic Testing: Offers a range of DNA testing services, including cancer screening, disease risk assessment, and pharmacogenomics.
- Prevention and Wellness: Provides personalized prevention and wellness solutions, including health screening programs and lifestyle recommendations.
- Digital Health: Develops digital health platforms and applications to deliver personalized healthcare services and connect patients with healthcare providers.
Leadership and Structure
Avanish Sahai serves as the Chief Executive Officer. The company operates with a board of directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- CircleDNA: A consumer DNA test that provides insights into health risks, ancestry, and lifestyle traits. It is one of their key revenue drivers. Competitors include 23andMe and AncestryDNA. Market share is estimated around 5% in the overall consumer DNA testing market, however their core focus is in Asia, where they have a greater foothold.
- ColoClear: A non-invasive stool DNA screening test for colorectal cancer detection. This is a fast growing part of their testing menu. Key competitors are Exact Sciences (EXAS) and Guardant Health (GH). Market share is still emerging but has strong upside potential.
- iGenes: Cancer diagnostics focused on personalized treatment decision making.
Market Dynamics
Industry Overview
The genomic and diagnostic testing market is experiencing significant growth, driven by increasing awareness of personalized medicine, advancements in technology, and growing prevalence of chronic diseases.
Positioning
Prenetics is positioned as a leader in personalized healthcare, offering a comprehensive range of genomic and diagnostic testing services. Its competitive advantages include its strong technology platform, international presence, and focus on early disease detection.
Total Addressable Market (TAM)
The global molecular diagnostics market is expected to reach approximately $16 billion. Prenetics is well positioned to capture a portion of this TAM with its diversified product portfolio.
Upturn SWOT Analysis
Strengths
- Strong technology platform
- International presence
- Focus on early disease detection
- Diversified product portfolio
Weaknesses
- Limited brand recognition compared to larger competitors
- Requires regulatory approvals in various markets
- Cash flow struggles due to acquisitions
Opportunities
- Expanding into new markets
- Developing new diagnostic tests
- Partnering with healthcare providers
- Leveraging the rising personalized medicine trend
Threats
- Intense competition
- Regulatory changes
- Economic downturn
- Data privacy concerns
Competitors and Market Share
Key Competitors
- EXAS
- ILMN
- TMO
- DGX
Competitive Landscape
Prenetics faces stiff competition from established players with greater resources. Its strength lies in its niche products and market focuses.
Major Acquisitions
ACT Genomics
- Year: 2022
- Acquisition Price (USD millions): 200
- Strategic Rationale: Expanded Prenetics' cancer genomics and diagnostics capabilities.
Growth Trajectory and Initiatives
Historical Growth: Prenetics has demonstrated growth through acquisitions and expansion of its testing portfolio.
Future Projections: Analyst estimates project future growth driven by demand for cancer screening, genomic testing, and precision medicine. However, these are speculative
Recent Initiatives: Recent initiatives include acquiring new companies that specialize in testing and forging partnerships with healthcare providers to expand reach.
Summary
Prenetics is operating in the rapidly growing molecular diagnostics space. The Company offers cancer and disease diagnostics testing for consumers. Their past aggressive acquisition strategy may be the cause of the recent cash flow challenges. The growth of this company will depend on successfully capturing market share away from entrenched competitors in a highly regulated market, and improving its financial performance to be cash flow positive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
- Market research reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prenetics Holding Company Limited
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-05-18 | Co-Founder, Chairperson & CEO Mr. Sheng Wu Yeung | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 285 | Website https://www.prenetics.com |
Full time employees 285 | Website https://www.prenetics.com |
Prenetics Global Limited, a consumer health company, focuses on empowering individuals to take control of their health through science-backed solutions in Hong Kong, Taiwan, the United States, and internationally. The company operates in three segments: Prevention, Diagnostics, and Consumer Health. It operates IM8 Health that sells health and wellness products; and provides fulfillment and distribution services for sports nutrition products under the Consumer Health segment. The company is also involved in the operation of CircleDNA, a consumer genetic testing brand that uses next-generation sequencing (NGS) technology to provide comprehensive insights into health, wellness, and genetic predispositions under Prevention segment.; and ACT Genomics that provides precision oncology testing services under the Diagnostics segment. In addition, it develops and commercializes multi-cancer early detection technologies. Further, the company offers a range of genomic profiling panels tailored for requirements and clinician needs. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.